Atlas Trials

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Clinical trial NCT05254990 · TERMINATED

Trial details

NCT number
NCT05254990
Sponsor
Dompé Farmaceutici S.p.A
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Infectious PneumoniaSevere COVID-19
Start date
2022-04-27
Primary completion
2024-07-29
Enrollment
414

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.